Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Acceptance of Evidence Transfer Within German Early Benefit Assessment of New Drugs for Pediatric and Adolescents Target Populations.
Pharmacoeconomics
January 2025
Institute for Health Services Research and Health Economics, Centre for Health and Society, Medical Faculty, Heinrich Heine University, Building: 12.49, Moorenstr. 5, 40225, Düsseldorf, Germany.
Background And Objective: In Germany, all new drugs undergo an early benefit assessment (EBA) by the decision-making body (G-BA). Due to limited access to clinical data in pediatric healthcare since 2017, evidence transfer has allowed for data from adult studies to be used in the EBA of pediatric drugs. This study examines the acceptance of evidence transfer, aiming to understand its correlation with granted added benefit.
View Article and Find Full Text PDFPredictors of knowledge level and awareness towards the principles and methodology evaluation of pharmacoeconomics in Saudi Arabia.
J Pharm Policy Pract
January 2025
Department of Pharmacy Practice, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
Background: Pharmaceutical expenditure has been a major concern for decision-makers worldwide. One strategy to control medication costs involves applying pharmacoeconomic (PE) methods in the approval and listing of new medications. Pharmacists need to possess the knowledge, skill, and competence to analyse and implement PE study findings.
View Article and Find Full Text PDFValue-Based Indication-Specific Pricing and Weighted-Average Pricing: Estimated Price and Cost Savings for Cancer Drugs.
Pharmacoeconomics
December 2024
Schumpeter School of Business and Economics, University of Wuppertal, Wuppertal, Germany.
Objectives: For US Medicare and Medicaid, single drug prices do not reflect the value of supplemental indications. Value-based indication-specific and weighted-average pricing has been suggested for drugs with multiple indications. Under indication-specific pricing, a distinct price is assigned to the differential value a drug offers in each indication.
View Article and Find Full Text PDFRelevance of patient-centered actigraphy measures in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a qualitative interview study.
BMC Pulm Med
December 2024
Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.
Background: Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are severe, progressive diseases characterized by key symptoms such as dyspnea and fatigue. These symptoms impair physical functioning, with patients struggling to perform their daily activities. One traditional measure of physical functioning and exercise capacity is the 6-minute walk test (6MWT).
View Article and Find Full Text PDFAugmenting clinical trials in asthma through digital technology, decentralised designs, and person-centric endpoints: opportunities and challenges.
Lancet Respir Med
December 2024
School of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand.
Article Synopsis
- * These technologies pave the way for decentralized clinical trials, allowing for a more inclusive study population, reduced costs, and faster access to new treatments.
- * The discussion includes the use of digital endpoints, different trial designs, a specific example of a fully decentralized asthma trial, and examines the pros and cons of these methods from various perspectives (clinicians, patients, and regulators).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!